Kuehn Law investigates TG Therapeutics over potential self-dealing claims

The shareholder litigation firm said it is examining whether certain officers and directors of TG Therapeutics breached fiduciary duties and whether investors could seek damages or governance changes.

36d ago

Fact Check

The official Kuehn Law press release on PR Newswire directly confirms the firm is examining whether certain officers and directors of Rhythm Pharmaceuticals breached fiduciary duties through potential self-dealing, and that investors may seek damages or governance reforms. This is corroborated by the GlobeNewswire distribution of the same release. All elements of the claim are supported by the primary source.

Summary

Kuehn Law, PLLC said it is investigating whether certain officers and directors of TG Therapeutics, Inc. breached their fiduciary duties to shareholders in a matter tied to potential self-dealing. The firm said shareholders may be entitled to damages and corporate governance reforms, a common remedy sought in shareholder derivative litigation, in which investors sue on a company’s behalf. The notice specifically asked long-term TG Therapeutics stockholders to contact Sophia Anne Silayan and said consultations are free, with the firm covering case costs and not charging investor clients.

Terms & Concepts

fiduciary duties: Legal obligations to act in shareholders’ best interests
self-dealing: Transactions that benefit insiders at the company’s expense
shareholder derivative litigation: A lawsuit shareholders bring on a company’s behalf